LISA BOMGAARS to Dabigatran
This is a "connection" page, showing publications LISA BOMGAARS has written about Dabigatran.
Connection Strength
1.278
-
Dabigatran for Treatment and Secondary Prevention of Venous Thromboembolism in Pediatric Congenital Heart Disease. J Am Heart Assoc. 2024 Feb 20; 13(4):e028957.
Score: 0.219
-
Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia. Blood Adv. 2022 11 22; 6(22):5908-5923.
Score: 0.201
-
Anticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters in Pediatric Patients: Combined Data from Five Pediatric Clinical Trials. Thromb Haemost. 2022 Sep; 122(9):1573-1583.
Score: 0.197
-
Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism. J Thromb Haemost. 2021 05; 19(5):1259-1270.
Score: 0.179
-
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol. 2021 Jan; 8(1):e22-e33.
Score: 0.175
-
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Blood. 2020 02 13; 135(7):491-504.
Score: 0.166
-
Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability. J Thromb Haemost. 2017 11; 15(11):2147-2157.
Score: 0.141